ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin - Full Text View

Sponsor:	M.D. Anderson Cancer Center
Collaborator:	AstraZeneca
Information provided by (Responsible Party):	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00054691

Purpose

Primary Objectives:

To explore the activity of ZD1839 administered to patients with SCC of the skin who have locoregional recurrence and/or metastatic disease and are not amenable to a curative local approach.
Activity is defined in terms of objective response rate, based on Union International Contre le Cancer (UICC)/World Health Organization (WHO) Criteria.

Secondary Objectives:

To determine the duration of response and survival and the safety and toxicity profile in patients with squamous cell carcinoma of the skin.
To evaluate modulation of biological targets following daily administration of ZD1839 (250 mg) in patients with biopsy-proven squamous cell carcinoma of the skin.

Condition	Intervention	Phase
Skin Cancer	Drug: Iressa	Phase II

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Resource links provided by NLM:

MedlinePlus related topics: Cancer Skin Cancer

Drug Information available for: Epidermal Growth Factor ZD1839

U.S. FDA Resources

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:

Activity (objective response rate) of ZD1839 administered to patients with SCC of the skin who have locoregional recurrence and/or metastatic disease and are not amenable to a curative local approach. [ Time Frame: 6 Years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Duration of response and survival, and the safety and toxicity profile in patients, with squamous cell carcinoma of the skin. [ Time Frame: 6 Years ] [ Designated as safety issue: Yes ]
Modulation of biological targets following daily administration of ZD1839 (250 mg) in patients with biopsy-proven SCC of the skin. [ Time Frame: 6 Years ] [ Designated as safety issue: No ]

Estimated Enrollment:	40
Study Start Date:	May 2004
Estimated Primary Completion Date:	May 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Iressa (ZD1839)	Drug: Iressa 250 mg by mouth daily Other Names: ZD1839 Gefitinib

Detailed Description:

ZD1839 is a new drug that may slow or stop cell growth in humans.

Epidermal growth factor receptor (EGFR) may be involved in certain types of cancer, including squamous cell carcinoma of the skin. When EGFR is stimulated, a series of chemical reactions starts that results in a tumor being "told" to grow. ZD1839 tries to stop these reactions by blocking EGFR. This may stop tumors from growing.

Before treatment starts, participants will have a full medical history and physical exam. Participants will have routine lab tests (including about 2-4 teaspoons of blood), ECG (test to measure the electrical activity of the heart), a chest x-ray, and a CT (computerized tomography) scan or MRI (magnetic resonance imaging). These are done to learn the status of a participant's disease. Women able to have children must have a negative blood pregnancy test.

In this study, participants will take ZD1839 by mouth daily. Once the treatment has started, participants will return to the clinic before every treatment cycle (every 4 weeks) for the first 4 months then every 8 weeks thereafter. At these visits, participants will have a physical exam and blood tests will be performed. About 2-4 teaspoons of blood will be drawn at each visit. The doctor will also check on how participants are tolerating ZD1839 (side effects). Every 8 weeks, participants will have their tumor evaluated by radiographic scans. This may include either a CT or MRI and a chest X-ray.

During treatment, participants should not take any other medication, including non-prescription drugs such as aspirin or herbal products without the approval of their doctor.

Participants will continue taking the trial drug until the tumor grows, a severe side effect occurs, they withdraw consent, or the study is closed. The study will be closed 12 months after the last participant is enrolled.

THIS IS AN INVESTIGATIONAL STUDY. The FDA has approved ZD1839 for the treatment of advanced lung cancer, but the FDA has authorized ZD1839 for research only in the treatment of skin cancer. About 40 participants will take part in this study. All will be enrolled at M.D. Anderson.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Provision of written informed consent.
Pathologically confirmed locoregional recurrence and/or metastatic SCC of the skin not amenable to curative therapy (i.e., surgery or radiation).
Evaluable and/or measurable disease. (Based on UICC/WHO Criteria)
ECOG performance status 0-2.
Adequate hematologic function as defined by an absolute neutrophil count >= 1,500/mm3, a platelet count >= 100,000/mm3, a WBC >= 3,000/ mm3, and a hemoglobin level of >= 9 g/dl.
Up to one prior chemotherapy regimen.
At least a 2-week recovery from prior therapy toxicity.
Age 18 years or older.
Disease free from a previously treated malignancy, other than the disease under study, for greater than 3 years. Patients with a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix, completely resected breast cancer will not be excluded.
Women of childbearing potential and men must be willing to practice acceptable methods of birth control to prevent pregnancy.

Exclusion Criteria:

Prior ZD1839 or other EGFR inhibiting agents.
Other co-existing malignancies or malignancies diagnosed within the last 3 years with the exception of basal cell carcinoma or cervical cancer in situ.
Any unresolved chronic toxicity greater then CTC grade 2 from previous anticancer therapy.
Incomplete healing from previous oncologic or other major surgery.
Concommitant use of phenytoin, carbamazepine, barbiturates, rifampicin, St John's Wort. Patients taking anticoagulants must have coagulation parameters followed (i.e., PT or PTT).
ANC less than 1,500/mm**3 or platelets less than 100,000/mm**3.
Serum bilirubin greater than 1.25 times the upper limit of reference range (ULRR).
In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease, (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).
Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5 times the ULRR if no demonstrable liver metastases or greater than 5 times the ULRR in the presence of liver metastases.
Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial.
Pregnancy or breast feeding (women of child-bearing potential)
The patient has an uncontrolled seizure disorder or active neurological disease.
The patient has received any non-approved or investigational agent(s) within 30 days before Day 1 of study treatment.
Known, severe hypersensitivity to ZD1839 or any of the excipients of this product.
Any evidence of clinically active ILD (patients with chronic, stable radiographic changes who are asymptomatic need not be excluded).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00054691

Locations

United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

AstraZeneca

Investigators

Principal Investigator:

Edward Kim, MD

M.D. Anderson Cancer Center

More Information

Additional Information:

The University of Texas M.D.Anderson Cancer Center This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00054691 History of Changes
Other Study ID Numbers:	ID02-282
Study First Received:	February 6, 2003
Last Updated:	December 15, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:

Skin Cancer
Squamous Cell Carcinoma of the Skin
Gefitinib
ZD1839

Iressa
Epidermal Growth Factor Receptor
EGFR

Additional relevant MeSH terms:

Carcinoma
Skin Neoplasms
Carcinoma, Squamous Cell
Carcinoma, Basal Cell
Carcinoma, Basosquamous
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms by Site
Skin Diseases
Neoplasms, Squamous Cell

Neoplasms, Basal Cell
Mitogens
Gefitinib
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Protein Kinase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on February 09, 2012